Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1997 Feb;225(2):145–154. doi: 10.1097/00000658-199702000-00002

Clinical uses of gut peptides.

J Geoghegan 1, T N Pappas 1
PMCID: PMC1190643  PMID: 9065291

Abstract

OBJECTIVE: The authors review clinical applications of gut-derived peptides as diagnostic and therapeutic agents. SUMMARY BACKGROUND DATA: An increasing number of gut peptides have been evaluated for clinical use. Earlier uses as diagnostic agents have been complemented more recently by increasing application of gut peptides as therapeutic agents. METHOD: The authors conducted a literature review. RESULTS: Current experience with clinical use of gut peptides is described. Initial clinical applications focused on using secretomotor effects of gut peptides in diagnostic tests, many of which have now fallen into disuse. More recently, attention has been directed toward harnessing these secretomotor effects for therapeutic use in a variety of disorders, and also using the trophic effects of gut peptides to modulate gut mucosal growth in benign and malignant disease. Gut peptides have been evaluated in a variety of other clinical situations including use as adjuncts to imaging techniques, and modification of behaviors such as feeding and panic disorder. CONCLUSIONS: Gut peptides have been used successfully in an increasing variety of clinical conditions. Further refinements in analogue and antagonist design are likely to lead to even more selective agents that may have important clinical applications. Further studies are needed to identity and evaluate these new agents.

Full text

PDF
145

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbruzzese J. L., Gholson C. F., Daugherty K., Larson E., DuBrow R., Berlin R., Levin B. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas. 1992;7(2):165–171. doi: 10.1097/00006676-199203000-00006. [DOI] [PubMed] [Google Scholar]
  2. Andersen J., Ström M. Pentagastrin given during upper gastrointestinal endoscopy: a simple screening method for hypo- and achlorhydria. Gastrointest Endosc. 1992 Jan-Feb;38(1):47–48. doi: 10.1016/s0016-5107(92)70330-7. [DOI] [PubMed] [Google Scholar]
  3. Anderson J. V., Bloom S. R. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995. Scand J Gastroenterol Suppl. 1986;119:115–128. doi: 10.3109/00365528609087439. [DOI] [PubMed] [Google Scholar]
  4. Arcidiacono R., Gambitta P., Rossi A., Grosso C., Bini M., Zanasi G. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy. 1994 Nov;26(9):715–718. doi: 10.1055/s-2007-1009081. [DOI] [PubMed] [Google Scholar]
  5. Avgerinos A., Armonis A., Raptis S. Somatostatin and octreotide in the management of acute variceal hemorrhage. Hepatogastroenterology. 1995 Apr;42(2):145–150. [PubMed] [Google Scholar]
  6. Ballinger A., McLoughlin L., Medbak S., Clark M. Cholecystokinin is a satiety hormone in humans at physiological post-prandial plasma concentrations. Clin Sci (Lond) 1995 Oct;89(4):375–381. doi: 10.1042/cs0890375. [DOI] [PubMed] [Google Scholar]
  7. Barkin J. S., Reiner D. K., Deutch E. Sandostatin for control of catheter drainage of pancreatic pseudocyst. Pancreas. 1991 Mar;6(2):245–248. doi: 10.1097/00006676-199103000-00019. [DOI] [PubMed] [Google Scholar]
  8. Baron J. H., Griffen W. O., Jr, Alexander-Williams J. Use and abuse of gastric function tests by British and American gastric surgeons. Am J Dig Dis. 1975 Apr;20(4):370–376. doi: 10.1007/BF01237796. [DOI] [PubMed] [Google Scholar]
  9. Baron J. H., Williams J. A. Use of gastric function tests by British gastroenterologists. Br Med J. 1971 Jan 23;1(5742):196–199. doi: 10.1136/bmj.1.5742.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bassi C., Falconi M., Lombardi D., Briani G., Vesentini S., Camboni M. G., Pederzoli P. Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Italy. Italian Study Group. Digestion. 1994;55 (Suppl 1):41–47. doi: 10.1159/000201188. [DOI] [PubMed] [Google Scholar]
  11. Baxter J. N., Jenkins S. A., Day D. W., Roberts N. B., Cowell D. C., Mackie C. R., Shields R. Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br J Surg. 1985 May;72(5):382–385. doi: 10.1002/bjs.1800720516. [DOI] [PubMed] [Google Scholar]
  12. Begos D. G., Modlin I. M. Gastrin and colon cancer. Clarifying the controversy. J Clin Gastroenterol. 1994 Apr;18(3):189–193. [PubMed] [Google Scholar]
  13. Besson I., Ingrand P., Person B., Boutroux D., Heresbach D., Bernard P., Hochain P., Larricq J., Gourlaouen A., Ribard D. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med. 1995 Aug 31;333(9):555–560. doi: 10.1056/NEJM199508313330904. [DOI] [PubMed] [Google Scholar]
  14. Bianco J. A., Higano C., Singer J., Appelbaum F. R., McDonald G. B. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation. 1990 Jun;49(6):1194–1195. doi: 10.1097/00007890-199006000-00040. [DOI] [PubMed] [Google Scholar]
  15. Bienenstock J., Perdue M., Stanisz A., Stead R. Neurohormonal regulation of gastrointestinal immunity. Gastroenterology. 1987 Dec;93(6):1431–1434. doi: 10.1016/0016-5085(87)90277-0. [DOI] [PubMed] [Google Scholar]
  16. Binder M., Uhl W., Friess H., Malfertheiner P., Büchler M. W. Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages. Digestion. 1994;55 (Suppl 1):20–23. doi: 10.1159/000201184. [DOI] [PubMed] [Google Scholar]
  17. Bittner R., Butters M., Büchler M., Nägele S., Roscher R., Beger H. G. Glucose homeostasis and endocrine pancreatic function in patients with chronic pancreatitis before and after surgical therapy. Pancreas. 1994 Jan;9(1):47–53. doi: 10.1097/00006676-199401000-00007. [DOI] [PubMed] [Google Scholar]
  18. Bolondi L., Li Bassi S., Gaiani S., Barbara L. Sonography of chronic pancreatitis. Radiol Clin North Am. 1989 Jul;27(4):815–833. [PubMed] [Google Scholar]
  19. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry. 1991 Jul;48(7):603–610. doi: 10.1001/archpsyc.1991.01810310021005. [DOI] [PubMed] [Google Scholar]
  20. Bruley des Varannes S., Parys V., Ropert A., Chayvialle J. A., Rozé C., Galmiche J. P. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology. 1995 Jul;109(1):32–39. doi: 10.1016/0016-5085(95)90266-x. [DOI] [PubMed] [Google Scholar]
  21. Burroughs A. K. Octreotide in variceal bleeding. Gut. 1994;35(3 Suppl):S23–S27. doi: 10.1136/gut.35.3_suppl.s23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Cascinu S., Del Ferro E., Catalano G. A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer. 1995 Jan;71(1):97–101. doi: 10.1038/bjc.1995.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Catnach S. M., Fairclough P. D., Trembath R. C., O'Donnell L. J., McLean A. M., Law P. A., Wickham J. E. Effect of oral erythromycin on gallbladder motility in normal subjects and subjects with gallstones. Gastroenterology. 1992 Jun;102(6):2071–2076. doi: 10.1016/0016-5085(92)90334-u. [DOI] [PubMed] [Google Scholar]
  24. Cavallini G., Rigo L., Bovo P., Brunori M. P., Angelini G. P., Vaona B., Di Francesco V., Frulloni L., Cocco C., Perobelli L. Abnormal US response of main pancreatic duct after secretin stimulation in patients with acute pancreatitis of different etiology. J Clin Gastroenterol. 1994 Jun;18(4):298–303. doi: 10.1097/00004836-199406000-00008. [DOI] [PubMed] [Google Scholar]
  25. Civitelli S., Galgani P., Pacchiarotti M. C., Civitelli B., Marini M., Pedani M., Bernini A., Tanzini G. Gastrinemia e neoplasie colorettali. G Chir. 1994 May;15(5):219–222. [PubMed] [Google Scholar]
  26. Coraggio F., Scarpato P., Spina M., Lombardi S. Somatostatin and ranitidine in the control of iatrogenic haemorrhage of the upper gastrointestinal tract. Br Med J (Clin Res Ed) 1984 Jul 28;289(6439):224–224. doi: 10.1136/bmj.289.6439.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Crawley J. N., Corwin R. L. Biological actions of cholecystokinin. Peptides. 1994;15(4):731–755. doi: 10.1016/0196-9781(94)90104-x. [DOI] [PubMed] [Google Scholar]
  28. Curnow R. T., Carey R. M., Taylor A., Johanson A., Murad F. Somatostatin inhibition of insulin and gastrin hypersecretion in pancreatic islet-cell carcinoma. N Engl J Med. 1975 Jun 26;292(26):1385–1386. doi: 10.1056/NEJM197506262922606. [DOI] [PubMed] [Google Scholar]
  29. Degertekin H., Ertan A., Akdamar K., Yates R., Chen I., Coy D. H., Arimura A. Effects of somatostatin and a somatostatin agonist on diet-induced pancreatitis in mice. Peptides. 1985 Nov-Dec;6(6):1245–1247. doi: 10.1016/0196-9781(85)90457-7. [DOI] [PubMed] [Google Scholar]
  30. Denyer M. E., Cotton P. B. Pure pancreatic juice studies in normal subjects and patients with chronic pancreatitis. Gut. 1979 Feb;20(2):89–97. doi: 10.1136/gut.20.2.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Di Leo A., Ferrari L., Bajetta E., Bartoli C., Vicario G., Moglia D., Miceli R., Callegari M., Bono A. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology. Breast Cancer Res Treat. 1995 Jun;34(3):237–244. doi: 10.1007/BF00689715. [DOI] [PubMed] [Google Scholar]
  32. Doppman J. L., Miller D. L., Chang R., Maton P. N., London J. F., Gardner J. D., Jensen R. T., Norton J. A. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990 Jan;174(1):25–29. doi: 10.1148/radiology.174.1.2294556. [DOI] [PubMed] [Google Scholar]
  33. Dunn F. H., Christensen E. D., Reynolds J., Jones V., Fordtran J. S. Cholecystokinin cholecystography. Controlled evaluation in the diagnosis and management of patients with possible acalculous gallbladder disease. JAMA. 1974 May 20;228(8):997–1003. doi: 10.1001/jama.228.8.997. [DOI] [PubMed] [Google Scholar]
  34. Ebert M., Friess H., Beger H. G., Büchler M. W. Role of octreotide in the treatment of pancreatic cancer. Digestion. 1994;55 (Suppl 1):48–51. doi: 10.1159/000201189. [DOI] [PubMed] [Google Scholar]
  35. Ekundayo A. A., Lee C. Y., Goodlad R. A. Gastrin and the growth of the gastrointestinal tract. Gut. 1995 Feb;36(2):203–208. doi: 10.1136/gut.36.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Farthing M. J. Octreotide in the treatment of refractory diarrhoea and intestinal fistulae. Gut. 1994;35(3 Suppl):S5–10. doi: 10.1136/gut.35.3_suppl.s5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Figg W. D., Thibault A., Cooper M. R., Reid R., Headlee D., Dawson N., Kohler D. R., Reed E., Sartor O. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer. 1995 Apr 15;75(8):2159–2164. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  38. Fiorucci S., Distrutti E., Gerli R., Morelli A. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastroenterol. 1994 Apr;89(4):550–555. [PubMed] [Google Scholar]
  39. Fishbeyn V. A., Norton J. A., Benya R. V., Pisegna J. R., Venzon D. J., Metz D. C., Jensen R. T. Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993 Aug 1;119(3):199–206. doi: 10.7326/0003-4819-119-3-199308010-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Freier S., Eran M., Faber J. Effect of cholecystokinin and of its antagonist, of atropine, and of food on the release of immunoglobulin A and immunoglobulin G specific antibodies in the rat intestine. Gastroenterology. 1987 Dec;93(6):1242–1246. doi: 10.1016/0016-5085(87)90251-4. [DOI] [PubMed] [Google Scholar]
  41. Friess H., Beger H. G., Sulkowski U., Becker H., Hofbauer B., Dennler H. J., Büchler M. W. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg. 1995 Sep;82(9):1270–1273. doi: 10.1002/bjs.1800820938. [DOI] [PubMed] [Google Scholar]
  42. Fukumoto Y., Okita K., Yasunaga M., Konishi T., Yamasaki T., Ando M., Shirasawa H., Fuji T., Takemoto T. A new therapeutic trial of secretin in the treatment of intrahepatic cholestasis. Gastroenterol Jpn. 1989 Jun;24(3):298–307. doi: 10.1007/BF02774328. [DOI] [PubMed] [Google Scholar]
  43. Gama R., Marks V., Wright J., Teale J. D. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Clin Endocrinol (Oxf) 1995 Jul;43(1):117–122. doi: 10.1111/j.1365-2265.1995.tb01901.x. [DOI] [PubMed] [Google Scholar]
  44. Gillespie G., Elder J. B., Gillespie I. E., Kay A. W., Campbell E. H. The long term stability of the insulin test. Gastroenterology. 1970 May;58(5):625–632. [PubMed] [Google Scholar]
  45. Glaser J., Mann O., Pausch J. Diagnosis of chronic pancreatitis by means of a sonographic secretin test. Int J Pancreatol. 1994 Jun;15(3):195–200. doi: 10.1007/BF02924194. [DOI] [PubMed] [Google Scholar]
  46. Gorden P., Comi R. J., Maton P. N., Go V. L. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989 Jan 1;110(1):35–50. doi: 10.7326/0003-4819-110-1-35. [DOI] [PubMed] [Google Scholar]
  47. Gray J. L., Debas H. T., Mulvihill S. J. Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. Arch Surg. 1991 Oct;126(10):1231–1236. doi: 10.1001/archsurg.1991.01410340073010. [DOI] [PubMed] [Google Scholar]
  48. Griffen W. O., Jr, Bivins B. A., Rogers E. L., Shearer G. R., Liebschutz D., Lieber A. Cholecystokinin cholecystography in the diagnosis of gallbladder disease. Ann Surg. 1980 May;191(5):636–640. doi: 10.1097/00000658-198005000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Gullo L., Barbara L. Treatment of pancreatic pseudocysts with octreotide. Lancet. 1991 Aug 31;338(8766):540–541. doi: 10.1016/0140-6736(91)91102-z. [DOI] [PubMed] [Google Scholar]
  50. Gøtzsche P. C., Gjørup I., Bonnén H., Brahe N. E., Becker U., Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ. 1995 Jun 10;310(6993):1495–1498. doi: 10.1136/bmj.310.6993.1495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Hill A. D., Walsh T. N., Hamilton D., Freyne P., O'Hare N., Byrne P. J., Hennessy T. P. Erythromycin improves emptying of the denervated stomach after oesophagectomy. Br J Surg. 1993 Jul;80(7):879–881. doi: 10.1002/bjs.1800800726. [DOI] [PubMed] [Google Scholar]
  52. Hodge A. J., Masarei J. R., Catchpole B. N. The role of the sympathetic nervous system in hypoglycaemia-stimulated gastric secretion. Gut. 1972 May;13(5):341–345. doi: 10.1136/gut.13.5.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Hudd C., Euhus D. M., LaRegina M. C., Herbold D. R., Palmer D. C., Johnson F. E. Effect of cholecystokinin on human cholangiocarcinoma xenografted into nude mice. Cancer Res. 1985 Mar;45(3):1372–1377. [PubMed] [Google Scholar]
  54. Hughes C. A., Bates T., Dowling R. H. Cholecystokinin and secretin prevent the intestinal mucosal hypoplasia of total parenteral nutrition in the dog. Gastroenterology. 1978 Jul;75(1):34–41. [PubMed] [Google Scholar]
  55. Imamura M., Takahashi K., Isobe Y., Hattori Y., Satomura K., Tobe T. Curative resection of multiple gastrinomas aided by selective arterial secretin injection test and intraoperative secretin test. Ann Surg. 1989 Dec;210(6):710–718. doi: 10.1097/00000658-198912000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Jamar F., Fiasse R., Leners N., Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995 Apr;36(4):542–549. [PubMed] [Google Scholar]
  57. Jameson J. S., Rogers J., Misiewicz J. J., Raimundo A. H., Henry M. M. Oral or intravenous erythromycin has no effect on human distal colonic motility. Aliment Pharmacol Ther. 1992 Oct;6(5):589–595. doi: 10.1111/j.1365-2036.1992.tb00573.x. [DOI] [PubMed] [Google Scholar]
  58. Johnston D., Jepson K. Use of pentagastrin in a test of gastric acid secretion. Lancet. 1967 Sep 16;2(7516):585–588. doi: 10.1016/s0140-6736(67)90739-8. [DOI] [PubMed] [Google Scholar]
  59. Kameyama M., Nakamori S., Imaoka S., Yasuda T., Nakano H., Ohigashi H., Hiratsuka M., Sasaki Y., Kabuto T., Ishikawa O. [Adjuvant chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer]. Gan To Kagaku Ryoho. 1994 Sep;21(13):2169–2171. [PubMed] [Google Scholar]
  60. Kay G., Hine P., Braganza J. The pancreolauryl test. A method of assessing the combined functional efficacy of pancreatic esterase and bile salts in vivo? Digestion. 1982;24(4):241–245. doi: 10.1159/000198803. [DOI] [PubMed] [Google Scholar]
  61. Kayasseh L., Gyr K., Stalder G. A., Allgoewer M. Somatostatin in acute gastroduodenal haemorrhage. Lancet. 1978 Oct 14;2(8094):833–834. doi: 10.1016/s0140-6736(78)92605-3. [DOI] [PubMed] [Google Scholar]
  62. Khoo D., Hall E., Motson R., Riley J., Denman K., Waxman J. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer. 1994;30A(1):28–30. doi: 10.1016/s0959-8049(05)80012-7. [DOI] [PubMed] [Google Scholar]
  63. Kramer M. S., Cutler N. R., Ballenger J. C., Patterson W. M., Mendels J., Chenault A., Shrivastava R., Matzura-Wolfe D., Lines C., Reines S. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995 Apr 1;37(7):462–466. doi: 10.1016/0006-3223(94)00190-E. [DOI] [PubMed] [Google Scholar]
  64. Kvols L. K., Buck M., Moertel C. G., Schutt A. J., Rubin J., O'Connell M. J., Hahn R. G. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med. 1987 Aug;107(2):162–168. doi: 10.7326/0003-4819-107-2-162. [DOI] [PubMed] [Google Scholar]
  65. Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J., Hahn R. G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986 Sep 11;315(11):663–666. doi: 10.1056/NEJM198609113151102. [DOI] [PubMed] [Google Scholar]
  66. Lamers C. B., Bijlstra A. M., Harris A. G. Octreotide, a long-acting somatostatin analog, in the management of postoperative dumping syndrome. An update. Dig Dis Sci. 1993 Feb;38(2):359–364. doi: 10.1007/BF01307556. [DOI] [PubMed] [Google Scholar]
  67. Lennard T. W., Farndon J. R., Taylor R. M. Acalculous biliary pain: diagnosis and selection for cholecystectomy using the cholecystokinin test for pain reproduction. Br J Surg. 1984 May;71(5):368–370. doi: 10.1002/bjs.1800710521. [DOI] [PubMed] [Google Scholar]
  68. Lennon J. R., Sircus W., Bloom S. R., Mitchell S. J., Polak J. M., Besser G. M., Hall R., Coy D. H., Kastin A. J., Schally A. V. Proceedings: Investigation and treatment of a recurrent vipoma. Gut. 1975 Oct;16(10):821–822. [PubMed] [Google Scholar]
  69. Lieverse R. J., Masclee A. A., Jansen J. B., Rovati L. C., Lamers C. B. Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women. Biol Psychiatry. 1995 Mar 1;37(5):331–335. doi: 10.1016/0006-3223(94)00136-Q. [DOI] [PubMed] [Google Scholar]
  70. Lipp R. W., Silly H., Ranner G., Dobnig H., Passath A., Leb G., Krejs G. J. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med. 1995 Jan;36(1):13–18. [PubMed] [Google Scholar]
  71. Magnusson I., Ihre T., Johansson C., Seligson U., Törngren S., Uvnäs-Moberg K. Randomised double blind trial of somatostatin in the treatment of massive upper gastrointestinal haemorrhage. Gut. 1985 Mar;26(3):221–226. doi: 10.1136/gut.26.3.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Malfertheiner P., Mayer D., Büchler M., Domínguez-Muñoz J. E., Schiefer B., Ditschuneit H. Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide. Gut. 1995 Mar;36(3):450–454. doi: 10.1136/gut.36.3.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Marsh H. M., Martin J. K., Jr, Kvols L. K., Gracey D. R., Warner M. A., Warner M. E., Moertel C. G. Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. Anesthesiology. 1987 Jan;66(1):89–91. doi: 10.1097/00000542-198701000-00021. [DOI] [PubMed] [Google Scholar]
  74. McGuigan J. E., Wolfe M. M. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology. 1980 Dec;79(6):1324–1331. [PubMed] [Google Scholar]
  75. Meko J. B., Norton J. A. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med. 1995;46:395–411. doi: 10.1146/annurev.med.46.1.395. [DOI] [PubMed] [Google Scholar]
  76. Middleton G. W., Williams J. H. Is gall bladder ejection fraction a reliable predictor of acalculous gall bladder disease? Nucl Med Commun. 1992 Dec;13(12):894–896. doi: 10.1097/00006231-199212000-00007. [DOI] [PubMed] [Google Scholar]
  77. Miller R. E., Chernish S. M., Greenman G. F., Maglinte D. D., Rosenak B. D., Brunelle R. L. Gastrointestinal response to minute doses of glucagon. Radiology. 1982 May;143(2):317–320. doi: 10.1148/radiology.143.2.7071331. [DOI] [PubMed] [Google Scholar]
  78. Morris D. L., Charnley R. M., Ballantyne K. C., Jones J. A pilot randomized control trial of proglumide (a gastrin receptor antagonist) in advanced colorectal cancer. Eur J Surg Oncol. 1990 Oct;16(5):423–425. [PubMed] [Google Scholar]
  79. Mulvihill S., Passaro E., Jr, Debas H., Yamada T. Severe diarrhea after colonic pseudo-obstruction: treatment with somatostatin. N Engl J Med. 1984 Feb 16;310(7):467–468. doi: 10.1056/NEJM198402163100719. [DOI] [PubMed] [Google Scholar]
  80. Newman C. B., Melmed S., Snyder P. J., Young W. F., Boyajy L. D., Levy R., Stewart W. N., Klibanski A., Molitch M. E., Gagel R. F. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab. 1995 Sep;80(9):2768–2775. doi: 10.1210/jcem.80.9.7673422. [DOI] [PubMed] [Google Scholar]
  81. Olsen J. O., Pozderac R. V., Hinkle G., Hill T., O'Dorisio T. M., Schirmer W. J., Ellison E. C., O'Dorisio M. S. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995 Jul;25(3):251–261. doi: 10.1016/s0001-2998(95)80014-x. [DOI] [PubMed] [Google Scholar]
  82. Pacini F., Romei C., Miccoli P., Elisei R., Molinaro E., Mancusi F., Iacconi P., Basolo F., Martino E., Pinchera A. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery. 1995 Dec;118(6):1031–1035. doi: 10.1016/s0039-6060(05)80110-2. [DOI] [PubMed] [Google Scholar]
  83. Paran H., Neufeld D., Mayo A., Shwartz I., Singer P., Kaplan O., Skornik Y., Klausner J., Freund U. Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg. 1995 Aug;181(2):121–124. [PubMed] [Google Scholar]
  84. Peeters T. L., Muls E., Janssens J., Urbain J. L., Bex M., Van Cutsem E., Depoortere I., De Roo M., Vantrappen G., Bouillon R. Effect of motilin on gastric emptying in patients with diabetic gastroparesis. Gastroenterology. 1992 Jan;102(1):97–101. doi: 10.1016/0016-5085(92)91788-6. [DOI] [PubMed] [Google Scholar]
  85. Pilot M. A. Macrolides in roles beyond antibiotic therapy. Br J Surg. 1994 Oct;81(10):1423–1429. doi: 10.1002/bjs.1800811006. [DOI] [PubMed] [Google Scholar]
  86. Primignani M., Andreoni B., Carpinelli L., Capria A., Rocchi G., Lorenzini I., Staudacher C., Beretta L., Motta R., de Franchis R. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. New Italian Endoscopic Club. Hepatology. 1995 May;21(5):1322–1327. [PubMed] [Google Scholar]
  87. Read R. C., Doherty J. E. Cardiovascular effects of induced insulin hypoglycemia in man during the Hollander test. Am J Surg. 1970 Feb;119(2):155–162. doi: 10.1016/0002-9610(70)90027-9. [DOI] [PubMed] [Google Scholar]
  88. Robbs J. V., Bank S., Marks I. N., Louw J. H. Selection of operation for duodenal ulcer based on acid secretory studies--a reappraisal. Br J Surg. 1973 Aug;60(8):601–605. doi: 10.1002/bjs.1800600805. [DOI] [PubMed] [Google Scholar]
  89. Romanus M. E., Neal J. A., Dilley W. G., Leight G. S., Linehan W. M., Santen R. J., Farndon J. R., Jones R. S., Wells S. A., Jr Comparison of four provocative tests for the diagnosis of gastrinoma. Ann Surg. 1983 May;197(5):608–617. doi: 10.1097/00000658-198305000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Rosenberg L., Barkun A. N., Denis M. H., Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer. 1995 Jan 1;75(1):23–28. doi: 10.1002/1097-0142(19950101)75:1<23::aid-cncr2820750106>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  91. SUN D. C., SHAY H. Pancreozymin-secretin test. The combined study of serum enzymes and duodenal contents in the diagnosis of pancreatic disease. Gastroenterology. 1960 Apr;38:570–581. [PubMed] [Google Scholar]
  92. Sancho J. J., di Costanzo J., Nubiola P., Larrad A., Beguiristain A., Roqueta F., Franch G., Oliva A., Gubern J. M., Sitges-Serra A. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula. Br J Surg. 1995 May;82(5):638–641. doi: 10.1002/bjs.1800820521. [DOI] [PubMed] [Google Scholar]
  93. Schwartz T. W., Rehfeld J. F., Stadil F., Larson L. I., Chance R. E., Moon N. Pancreatic-polypeptide response to food in duodenal-ulcer patients before and after vagotomy. Lancet. 1976 May 22;1(7969):1102–1105. doi: 10.1016/s0140-6736(76)90065-9. [DOI] [PubMed] [Google Scholar]
  94. Schwartz T. W., Stenquist B., Olbe L. Cephalic phase of pancreatic-polypeptide secretion studied by sham feeding in man. Scand J Gastroenterol. 1979;14(3):313–320. doi: 10.3109/00365527909179889. [DOI] [PubMed] [Google Scholar]
  95. Seymour N. E., Brunicardi F. C., Chaiken R. L., Lebovitz H. E., Chance R. E., Gingerich R. L., Elahi D., Andersen D. K. Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. Surgery. 1988 Aug;104(2):119–129. [PubMed] [Google Scholar]
  96. Sharma S. S., Bhargava N., Mathur S. C. Effect of oral erythromycin on colonic transit in patients with idiopathic constipation. A pilot study. Dig Dis Sci. 1995 Nov;40(11):2446–2449. doi: 10.1007/BF02063252. [DOI] [PubMed] [Google Scholar]
  97. Sitzmann J. V., Pitt H. A., Steinborn P. A., Pasha Z. R., Sanders R. C. Cholecystokinin prevents parenteral nutrition induced biliary sludge in humans. Surg Gynecol Obstet. 1990 Jan;170(1):25–31. [PubMed] [Google Scholar]
  98. Smith J. P., Kramer S. T., Solomon T. E. CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium. Regul Pept. 1991 Feb 26;32(3):341–349. doi: 10.1016/0167-0115(91)90027-e. [DOI] [PubMed] [Google Scholar]
  99. Somerville K. W., Henry D. A., Davies J. G., Hine K. R., Hawkey C. J., Langman M. J. Somatostatin in treatment of haematemesis and melaena. Lancet. 1985 Jan 19;1(8421):130–132. doi: 10.1016/s0140-6736(85)91903-8. [DOI] [PubMed] [Google Scholar]
  100. Soresi E., Bombardieri E., Chiti A., Boffi R., Invernizzi G., Crippa F., Maffioli L. Indium-111-DTPA-octreotide scintigraphy modulation by treatment with unlabelled somatostatin analogue in small-cell lung cancer. Tumori. 1995 Mar-Apr;81(2):125–127. doi: 10.1177/030089169508100210. [DOI] [PubMed] [Google Scholar]
  101. Stacher G., Steinringer H., Schmierer G., Schneider C., Winklehner S. Cholecystokinin octapeptide decreases intake of solid food in man. Peptides. 1982 Mar-Apr;3(2):133–136. doi: 10.1016/0196-9781(82)90041-9. [DOI] [PubMed] [Google Scholar]
  102. Stael A. P., Plukker J. T., Piers D. A., Rouwé C. W., Vermey A. Total thyroidectomy in the treatment of thyroid carcinoma in childhood. Br J Surg. 1995 Aug;82(8):1083–1085. doi: 10.1002/bjs.1800820825. [DOI] [PubMed] [Google Scholar]
  103. Stern M. A., Wolf D. C. Erythromycin as a prokinetic agent: a prospective, randomized, controlled study of efficacy in nasoenteric tube placement. Am J Gastroenterol. 1994 Nov;89(11):2011–2013. [PubMed] [Google Scholar]
  104. Sternlieb J. M., Aronchick C. A., Retig J. N., Dabezies M., Saunders F., Goosenberg E., Infantolino A., Ionna S., Maislin G., Wright S. H. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol. 1992 Nov;87(11):1561–1566. [PubMed] [Google Scholar]
  105. Sun Y. S., Brunicardi F. C., Druck P., Walfisch S., Berlin S. A., Chance R. E., Gingerich R. L., Elahi D., Andersen D. K. Reversal of abnormal glucose metabolism in chronic pancreatitis by administration of pancreatic polypeptide. Am J Surg. 1986 Jan;151(1):130–140. doi: 10.1016/0002-9610(86)90023-1. [DOI] [PubMed] [Google Scholar]
  106. Sunderland G. T., Carter D. C. Clinical application of the cholecystokinin provocation test. Br J Surg. 1988 May;75(5):444–449. doi: 10.1002/bjs.1800750516. [DOI] [PubMed] [Google Scholar]
  107. Svensson J. O., Gelin J., Svanvik J. Gallstones, cholecystectomy, and duodenogastric reflux of bile acid. Scand J Gastroenterol. 1986 Mar;21(2):181–187. doi: 10.3109/00365528609034644. [DOI] [PubMed] [Google Scholar]
  108. TRACY H. J., GREGORY R. A. PHYSIOLOGICAL PROPERTIES OF A SERIES OF SYNTHETIC PEPTIDES STRUCTURALLY RELATED TO GASTRIN I. Nature. 1964 Dec 5;204:935–938. doi: 10.1038/204935a0. [DOI] [PubMed] [Google Scholar]
  109. Takehara Y., Ichijo K., Tooyama N., Kodaira N., Fujiwara T., Yamamoto H., Watahiki H., Kaneko M. [Enhanced delineation of the pancreatic duct in MR cholangiopancreatography (MRCP) with a combined use of secretin]. Nihon Igaku Hoshasen Gakkai Zasshi. 1995 Mar;55(4):255–256. [PubMed] [Google Scholar]
  110. Teitelbaum D. H., Han-Markey T., Schumacher R. E. Treatment of parenteral nutrition-associated cholestasis with cholecystokinin-octapeptide. J Pediatr Surg. 1995 Jul;30(7):1082–1085. doi: 10.1016/0022-3468(95)90346-1. [DOI] [PubMed] [Google Scholar]
  111. Thornell E. Cholecystokinin (CCK) cholecystography and biliary pain. Br J Surg. 1985 Jul;72(7):585–586. doi: 10.1002/bjs.1800720729. [DOI] [PubMed] [Google Scholar]
  112. Topazian M. Acute pancreatitis, pancreatic duct obstruction, and the secretin-ultrasound test. J Clin Gastroenterol. 1994 Jun;18(4):277–279. doi: 10.1097/00004836-199406000-00003. [DOI] [PubMed] [Google Scholar]
  113. Torres A. J., Landa I., Hernández F., Jover J. M., Suárez A., Arias J., Cuberes R., Santoyo J., Fernández R., Calleja J. Somatostatin in the treatment of severe upper gastrointestinal bleeding: a multicentre controlled trial. Br J Surg. 1986 Oct;73(10):786–789. doi: 10.1002/bjs.1800731009. [DOI] [PubMed] [Google Scholar]
  114. Tulassay Z., Papp J. The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. Gastrointest Endosc. 1991 Jan-Feb;37(1):48–50. doi: 10.1016/s0016-5107(91)70620-2. [DOI] [PubMed] [Google Scholar]
  115. Vinik A. I., Tsai S., Moattari A. R., Cheung P. Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Surgery. 1988 Nov;104(5):834–842. [PubMed] [Google Scholar]
  116. Wiseman G. A., Kvols L. K. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med. 1995 Jul;25(3):272–278. doi: 10.1016/s0001-2998(95)80016-6. [DOI] [PubMed] [Google Scholar]
  117. Witzig T. E., Letendre L., Gerstner J., Schroeder G., Mailliard J. A., Colon-Otero G., Marschke R. F., Windschitl H. E. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol. 1995 Aug;13(8):2012–2015. doi: 10.1200/JCO.1995.13.8.2012. [DOI] [PubMed] [Google Scholar]
  118. Yeo C. J., Barry M. K., Sauter P. K., Sostre S., Lillemoe K. D., Pitt H. A., Cameron J. L. Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized, placebo-controlled trial. Ann Surg. 1993 Sep;218(3):229–238. doi: 10.1097/00000658-199309000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. van Megen H. J., den Boer J. A., Westenberg H. G. On the significance of cholecystokinin receptors in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Dec;18(8):1235–1246. doi: 10.1016/0278-5846(94)90090-6. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES